# ARTICLE IN PRESS

International Journal of Pharmaceutics xxx (2012) xxx-xxx



Contents lists available at SciVerse ScienceDirect

## International Journal of Pharmaceutics

journal homepage: www.elsevier.com/locate/ijpharm



Pharmaceutical Nanotechnology

### Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension

Jing-jing Guo<sup>a,1</sup>, Peng-Fei Yue<sup>b,c,1</sup>, Jun-lan Lv<sup>a</sup>, Jin Han<sup>a,\*</sup>, Shan-shan Fu<sup>a</sup>, Shi-xiao Jin<sup>a</sup>, Shi-ying Jin<sup>a</sup>, Hai-Long Yuan<sup>a,\*</sup>

- <sup>a</sup> 302 Hospital of PLA&PLA Institute of Chinese Materia Medica, Beijing 100039, China
- <sup>b</sup> Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, China
- <sup>c</sup> Shanghai University of Traditional Chinese Medicine, Institute of Chinese Materia Medica, Shanghai, China

#### ARTICLE INFO

#### Article history: Received 28 August 2012 Received in revised form 25 October 2012 Accepted 26 November 2012 Available online xxx

Keywords: Herpetrione Nanosuspension Dissolution Bioavailability Activity assay

#### ABSTRACT

Herpetrione (HPE), is a new compound extracted from Herpetospermum caudigerum, which is proved to be a novel and potent antiviral agent. However, due to poor water solubility, oral bioavailability of the drug was relatively low. To improve the dissolution and absorption of the drug, formulation of HPE as nanosuspension has been performed in this study. HPE nanosuspension were produced by high pressure homogenization and transformed into dry powder by lyophilization. The nanosuspension was then investigated using photon correlation spectroscopy (PCS), zeta potential measurement, SEM and PXRD. To verify the theoretical hypothesis on the benefit of decreased particle size and increased surface area, in vitro dissolution characterization and in vivo pharmacokinetics were investigated. The inhibitory effect on HBsAg, HBeAg, and HBV-DNA of HPE nanosuspension in 2.2.15 cells was studied. Results showed that a narrow size distributed nanosuspension with a mean particle size of  $286 \pm 1.3$  nm, a polydispersity index of  $0.18 \pm 0.06$  and a zeta potential of  $-26.9 \pm 2.4$  mV was obtained. The result of PXRD showed that HPE was amorphous state in both coarse powder and nanosuspension. In the *in vitro* dissolution test, HPE nanosuspension showed an increased dissolution velocity markedly. In the in vivo evaluation, compared to coarse HPE, nanosuspension exhibited significant increase in  $AUC_{0-t}$ ,  $C_{max}$  and decrease in  $T_{max}$ , MRT. The inhibitory effect of HBsAg, HBeAg, and HBV-DNA of 2.2.15 cells treated by HPE nanosuspension were stronger than those of the HPE. The in vitro activity experiments provided evidence for an enhanced efficacy of the HPE nanosuspension formulation compared to HPE coarse suspension. These results revealed that particle size reduction could enhance HPE dissolution rate and absorption in gastrointestinal tract, and nanosuspension might be a good choice for oral delivery of poor bioavailability drug like HPE.

© 2012 Elsevier B.V. All rights reserved.

#### 1. Introduction

Herpetospermum caudigerum is a well-known Tibetan medicine in China. It is the dry, mature seed of *H. caudigerum* Wall, which grows widely in the southwest of China, Nepal and the northeast of India. In Tibet it is widely used in traditional medicine for the treatment of liver diseases, cholic diseases, and dyspepsia (Wu, 1985; Chinese Pharmacopoeia Committee, 1995). In the previous investigation, a large amount of lignans have been isolated from *H. caudigerum* (Kaouadji et al., 1978, 1979, 1987; Kaouadji and Favre, 1984a,b) and showed positive activity in the inhibit hepatitis b virus test (Han et al., 2005, 2006). Herpetrione (HPE, Fig. 1), extracted from *H. caudigerum*, is a promising and potent antiviral agent (Yuan et al., 2011). However, pharmacokinetic stud-

0378-5173/\$ – see front matter © 2012 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.ijpharm.2012.11.039 ies of HPE in rats showed the drug had a less than 12% oral bioavailability, which was due to poor water solubility of drug (47.6  $\mu$ g/mL). In consideration of further pharmaceutical use of the drug, we must overcome the problem of its poor solubility. Size reduction to nanometer range has been shown to be a very promising approach as it increases surface area and thus leads to enhanced dissolution characteristics and increased system exposure (Hecq et al., 2006). Therefore, the poor solubility of drug may be overcome by particle size reduction using nanoscience approaches (lo et al., 2010).

One of the nanoscience approaches that have quickly gained a proven record in the pharmaceutical field is the nanosuspension (Van Eerdenbrugh et al., 2008). Producing drugs into the form of nanosuspension has been shown to be more cost effective, technically simpler, alternative and particular for poorly soluble compounds (Io et al., 2010). Nanosuspension is a sub-micron colloidal dispersion of pure particles of the drug, which is stabilized by surfactants (Rabinow, 2004). The main advantages of nanosuspension are the small particle size and increased surface area which can lead to an enhanced dissolution rate and improved

<sup>\*</sup> Corresponding authors. Tel.: +86 10 66933324; fax: +86 10 63879915. E-mail addresses: J.Hanpharm@gmail.com (J. Han), jxtcmi215@126.com H.-L. Yuan).

<sup>&</sup>lt;sup>1</sup> Jing-jing Guo and Peng-fei Yue contributed equally to this work as first author.